Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

被引：2

作者：

Shah, Bijal D. ^{[1
]}

Ghobadi, Armin ^{[2
]}

Oluwole, Olalekan O. ^{[3
]}

Logan, Aaron C. ^{[4
]}

Boissel, Nicolas ^{[5
]}

Cassaday, Ryan D. ^{[6
]}

Leguay, Thibaut ^{[7
]}

Bishop, Michael R. ^{[8
]}

Topp, Max S. ^{[9
]}

Tzachanis, Dimitrios ^{[10
]}

O'Dwyer, Kristen M. ^{[11
]}

Arellano, Martha L. ^{[12
]}

Lin, Yi ^{[13
]}

Baer, Maria R. ^{[14
]}

Schiller, Gary J. ^{[15
]}

Park, Jae H. ^{[16
]}

Subklewe, Marion ^{[17
]}

Abedi, Mehrdad ^{[18
]}

Minnema, Monique C. ^{[19
]}

Wierda, William G. ^{[20
]}

DeAngelo, Daniel J. ^{[21
]}

Stiff, Patrick ^{[22
]}

Jeyakumar, Deepa ^{[23
]}

Dong, Jinghui ^{[24
]}

Adhikary, Sabina ^{[24
]}

Zhou, Lang ^{[24
]}

Schuberth, Petra C. ^{[24
]}

Faghmous, Imi ^{[24
]}

Masouleh, Behzad Kharabi ^{[24
]}

Houot, Roch ^{[25
,26
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Washington Univ, Sch Med, St Louis, MO USA

[3] Vanderbilt Univ, Canc Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA

[4] UCSF Med Ctr, San Francisco, CA USA

[5] Hop St Louis, Paris, France

[6] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA

[7] CHU Bordeaux, Serv Hematol Clin & Therapie Cellulaire, Hop Haut Leveque, Bordeaux, France

[8] Univ Chicago Med, Chicago, IL USA

[9] Univ Klinikum WUrzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[10] Univ Calif San Diego, San Diego, CA 92103 USA

[11] Univ Rochester, Wilmot Canc Inst, Rochester, NY USA

[12] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[13] Mayo Clin, Div Hematol, Rochester, MN USA

[14] Univ Maryland, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[15] UCLA, David Geffen Sch Med, Los Angeles, CA 90095 USA

[16] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[17] Ludwig Maximilians Univ Munchen, Munich, Germany

[18] Univ Calif Davis, Davis Comprehens Canc Ctr, Sacramento, CA 95817 USA

[19] Univ Med Ctr Utrecht, Behalf HOVON LLPC, Utrecht, Netherlands

[20] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[21] Dana Farber Canc Inst, Boston, MA USA

[22] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA

[23] Univ Calif Irvine, Irvine Med Ctr, Orange, CA 92668 USA

[24] Kite, Santa Monica, CA USA

[25] Univ Rennes, INSERM, CHU Rennes, Rennes, France

[26] EFS, Rennes, France

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-158248

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3158 / 3161

页数：4

共 50 条

[21] Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA)
Gupta, Vishal K.
Roloff, Gregory W.
Muffly, Lori S.
Aldoss, Ibrahim
Kopmar, Noam E.
Lin, Chenyu
Dekker, Simone E.
Jeyakumar, Nikeshan
O'Connor, Timothy E.
Zhang, Amy
Miller, Katharine
Dykes, Kaitlyn C.
Ahmed, Mohamed
Bradshaw, Danielle
Mercadal, Santiago
Schwartz, Marc
Tracy, Sean
Dholaria, Bhagirathbhai
Kubiak, Michal
Mukherjee, Akash
Majhail, Navneet
Battiwalla, Minoo
Mountjoy, Luke
Malik, Shabaz
Mathews, John
Shaughnessy, Paul
Logan, Aaron C.
Ladha, Abdullah
Yaghmour, George
Advani, Anjali S.
Stefan, Maryann
Guzowski, Caitlin
Hoeg, Rasmus T.
Hilal, Talal
Moore, Jozal
O'Dwyer, Kristen M.
Tsai, Stephanie B.
Sasine, Joshua
Lee, Catherine J.
Kota, Vamsi K.
Koura, Divya
Veeraputhiran, Muthu
Blunk, Betsy
Leonard, Jessica T.
Stock, Wendy
Galal, Ahmed
Pullarkat, Vinod
Cassaday, Ryan D.
Shah, Bijal D.
Faramand, Rawan
BLOOD, 2023, 142
[22] Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)
Shah, Bijal D.
Stock, Wendy
Wierda, William G.
Oluwole, Olalekan
Holmes, Houston
Schiller, Gary J.
Topp, Max S.
Kersten, Marie Jose
Houot, Roch
Boissel, Nicolas
Mojadidi, Michelle
Xue, Allen
Mardiros, Armen
Jiang, Yizhou
Shen, Tong
Aycock, Jeff S.
Stout, Shanna
Wiezorek, Jeffrey S.
Jain, Rajul
BLOOD, 2017, 130
[23] Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study
Kopmar, Noam E.
Gooley, Ted
Roloff, Gregory W.
Aldoss, Ibrahim
Lin, Chenyu
Dekker, Simone E.
Gupta, Vishal K.
Jeyakumar, Nikeshan
O'connor, Timothy
Dykes, Kaitlyn C.
Ahmed, Mohamed
Zambrano, Hector
Bradshaw, Danielle
Mercadal, Santiago
Schwartz, Marc
Tracy, Sean
Dholaria, Bhagirathbhai
Kubiak, Michal
Mukherjee, Akash
Majhail, Navneet
Battiwalla, Minoo
Mountjoy, Luke
Malik, Shabaz
Shaughnessy, Paul
Mathews, John
Logan, Aaron C.
Ladha, Abdullah
Yaghmour, George
Advani, Anjali S.
Stefan, Maryann
Guzowski, Caitlin
Hoeg, Rasmus T.
Hilal, Talal
Moore, Jozal
O'Dwyer, Kristen M.
Tsai, Stephanie B.
Sasine, Joshua
Solh, Melhem M.
Lee, Catherine J.
Kota, Vamsi K.
Koura, Divya
Veeraputhiran, Muthu
Blunk, Betsy
Leonard, Jessica T.
Oliai, Caspian H.
Bachanova, Veronika
Stock, Wendy
Galal, Ahmed
Pullarkat, Vinod
Shah, Bijal D.
BLOOD, 2023, 142
[24] The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Aldoss, Ibrahim
Roloff, Gregory W.
Advani, Anjali S.
Kopmar, Noam E.
Lin, Chenyu
Dekker, Simone E.
Gupta, Vishal K.
Jeyakumar, Nikeshan
O'Connor, Timothy E.
Zhang, Amy
Miller, Katharine
Dykes, Kaitlyn C.
Ahmed, Mohamed
Zambrano, Hector
Bradshaw, Danielle
Mercadal, Santiago
Schwartz, Marc
Tracy, Sean
Dholaria, Bhagirathbhai
Kubiak, Michal
Mukherjee, Akash
Majhail, Navneet
Battiwalla, Minoo
Mountjoy, Luke
Malik, Shahbaz A.
Mathews, John
Shaughnessy, Paul
Logan, Aaron C.
Ladha, Abdullah
Yaghmour, George
Stefan, Maryann
Guzowski, Caitlin
Hoeg, Rasmus T.
Hilal, Talal
Moore, Jozal
O'Dwyer, Kristen M.
Tsai, Stephanie B.
Sasine, Joshua
Solh, Melhem M.
Lee, Catherine J.
Kota, Vamsi K.
Koura, Divya
Veeraputhiran, Muthu
Blunk, Betsy
Leonard, Jessica T.
Oliai, Caspian H.
Bachanova, Veronika
Stock, Wendy
Galal, Ahmed
Pullarkat, Vinod
BLOOD, 2023, 142
[25] Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
Shah, Bijal D.
Wierda, William G.
Schiller, Gary J.
Bishop, Michael Russell
Castro, Januario E.
Sabatino, Marianna
Bot, Adrian
Mardiros, Armen
Rossi, John
Jiang, Yizhou
Navale, Lynn
Stout, Shanna
Aycock, Jeff
Wiezorek, Jeffrey S.
Jain, Rajul K.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[26] KTE-C19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY IN ADULTS WITH HIGH-BURDEN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL): UPDATED RESULTS FROM PHASE 1/2 OF ZUMA-3
Shah, B.
Wierda, W. G.
Schiller, G. J.
Bishop, M. R.
Castro, J. E.
Sabatino, M.
Mardiros, A.
Rossi, J.
Jiang, Y.
Navale, L.
Stout, S.
Aycock, J.
Wiezorek, J.
Jain, R.
HAEMATOLOGICA, 2017, 102 : 200 - 200
[27] Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.
Mueller, Karen Thudium
Grupp, Stephan A.
Maude, Shannon L.
Levine, John E.
Pulsipher, Michael
Boyer, Michael W.
August, Keith Jason
Myers, Gary Douglas
Awasthi, Rakesh
Waldron, Edward K.
Bubuteishvili-Pacaud, Lida
Taran, Tanya
Cota, Mariana
Tam, Constantine Si Lun
Jager, Ulrich
Foley, Ronan
Borchmann, Peter
Schuster, Stephen J.
Waller, Edmund K.
Laetsch, Theodore Willis
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[28] Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry
Wudhikarn, Kitsada
Bezerra, Evandro
Yang, Yang
Perales, Miguel-Angel
Jain, Nitin
Gergis, Usama
Aribi, Ahmed
Hill, Laquisa
Leonard, Jessica T.
Lutfi, Forat
Kim, Soyoung
Bye, Matthew
Hu, Zhen-Huan
Wang, Hai-Lin
Luo, Zhong-Cheng
Siddiqi, Rubina
Khalid, Rita Damico
Speiser, Jessica
Pasquini, Marcelo C.
Kebriaei, Partow
Muffly, Lori
BLOOD, 2024, 144 : 5092 - 5093
[29] Early results of a safety and efficacy study of allogeneic TruUCAR™ GC502 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
Li, Shiqi
Wang, Xinxin
Yuan, Zhongtao
Liu, Lin
Li, Yu
Liu, Jia
He, Jiaping
Li, Zhimin
Zhao, Wei
Ge, Jianning
Ni, Yajin
Shen, Lianjun
Cao, Wei
Zhang, Xi
Sersch, Martina
Wang, Sanbin
CANCER RESEARCH, 2022, 82 (12)
[30] Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Wierda, William G.
Bishop, Michael R.
Oluwole, Olalekan O.
Logan, Aaron C.
Baer, Maria R.
Donnellan, William B.
O'Dwyer, Kristen M.
Castro, Januario E.
Schiller, Gary J.
Holmes, Houston
Abedi, Mehrdad
Ghobadi, Armin
Arellano, Martha L.
Malone, Adriana K.
Pagel, John M.
Mardiros, Armen
Shen, Tong
Vezan, Remus
Jain, Rajul K.
Shah, Bijal D.
BLOOD, 2018, 132

← 1 2 3 4 5 →